Thyme Care Raises Over $125 Million and Forms Thyme Companies
Thyme Care raised over $125 million in Series E funding led by Morgan Health, with participation from Humana, CVS Health Ventures, and other investors, the company announced in a press release.
Other participants included AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. Thyme Care said its services are available to more than 10.5 million people across all 50 states and that it manages more than $7 billion in oncology spending.
Alongside the funding, Thyme Care formed Thyme Companies as a parent entity for new independent oncology businesses. Areas in active development include adoption of lower cost biosimilars and clinical trial accrual, with the first business expected to launch later this year.
Co founder Robin Shah will serve as executive chairman of Thyme Companies. Thyme Care will continue under CEO Brad Diephuis, with Bobby Green serving as president and chief medical officer.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
More from: Funding
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more